Objective:

To evaluate the impact of distinct PD−1 inhibitors plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (RM−NPC).

Approach:

Key Findings:

• Pooled ORR was 64% and DCR was 94%.
• Toripalimab-based regimens achieved the highest ORR and longest median PFS of 21.4 months.
• Tislelizumab plus chemotherapy yielded the most favorable median OS of 45.3 months.
• Camrelizumab plus chemotherapy showed a median OS of 34.5 months.
• Pooled incidence of grade ≥3 TRAEs was 13%, with comparable safety profiles across all PD−1 inhibitors.

Interpretation:

Remove unsupported claims about efficacy and long-term survival benefits.

Limitations:

• The study included both randomized controlled trials and non-randomized studies, which may affect the robustness of the findings.
• The systematic review did not restrict to English publications, which may introduce variability in study quality.

Conclusion:

Revise to avoid unsupported claims and focus on findings without editorial interpretation.

Sources:

• Systematic Review Registration
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.